Terms: = Liver cancer AND PR, PGR, progesterone receptor
1911 results:
1. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
Yamaba S; Imai Y; Sugawara K; Uchida Y; Fuchigami A; Uchiya H; Nakayama N; Mochida S
PLoS One; 2024; 19(4):e0298770. PubMed ID: 38687817
[TBL] [Abstract] [Full Text] [Related]
2. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
3. Enhanced protein-metabolite correlation analysis: To investigate the association between Staphylococcus aureus mastitis and metabolic immune pathways.
Chen K; Hu B; Ren J; Deng X; Li Q; Zhang R; Zhang Y; Shen G; Liu S; Zhang J; Lu P
FASEB J; 2024 Apr; 38(7):e23587. PubMed ID: 38568835
[TBL] [Abstract] [Full Text] [Related]
4. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of deep learning model for predicting immune checkpoint inhibitor treatment efficacy on contrast-enhanced computed tomography images of hepatocellular carcinoma.
Nakao Y; Nishihara T; Sasaki R; Fukushima M; Miuma S; Miyaaki H; Akazawa Y; Nakao K
Sci Rep; 2024 Mar; 14(1):6576. PubMed ID: 38503827
[TBL] [Abstract] [Full Text] [Related]
6. Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome.
Yang F; Zhou L; Shen Y; Wang X; Fan X; Yang L
J Transl Med; 2024 Feb; 22(1):214. PubMed ID: 38424613
[TBL] [Abstract] [Full Text] [Related]
7. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
8. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level
Qin S; Pan H; Blanc JF; Grando V; Lim HY; Chang XY; O'Brate A; Stroh C; Friese-Hamim M; Albers J; Johne A; Faivre S
JCO Precis Oncol; 2024 Feb; 8():e2300328. PubMed ID: 38354329
[TBL] [Abstract] [Full Text] [Related]
9. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.
Yi L; Ning Z; Xu L; Shen Y; Zhu X; Yu W; Xie J; Meng Z
ESMO Open; 2024 Feb; 9(2):102239. PubMed ID: 38325225
[TBL] [Abstract] [Full Text] [Related]
10. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
Kikuchi K; Ogawa M; Sasaki A
J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
[TBL] [Abstract] [Full Text] [Related]
11. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
12. [Our Experience with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma].
Shimizu J; Yamashita M; Odagiri K; Takeyama H; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Dono K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1513-1515. PubMed ID: 38303325
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of Postoperative Recurrence of liver Metastasis after Gastrectomy for Gastric cancer-No Recurrence for Five Years after Twice liver Resections].
Fukumoto S; Yamamoto Y; Yanagawa S; Takaya M; Amioka J; Kaneko Y; Watanabe A; Nishina M; Mashima H; Sumi Y; Yamaki M; Kurayoshi M; Oshita A; Nakahara M; Noriyuki T
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1895-1896. PubMed ID: 38303244
[TBL] [Abstract] [Full Text] [Related]
14. [A Case of Triple Negative Breast cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
[TBL] [Abstract] [Full Text] [Related]
15. [A Case of HER2-Positive Advanced Breast cancer Who Was Able to Start and Continue Chemotherapy Despite liver Damage Due to Diffuse liver Metastasis].
Fujimoto T; Maeda N; Ioka T; Nagano H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1739-1741. PubMed ID: 38303191
[TBL] [Abstract] [Full Text] [Related]
16. [A Case of Recurrent Gastric cancer with Long-Term Control via Two Resections and Multidisciplinary Treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
17. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.
Liu D; Mu H; Liu C; Zhang W; Cui Y; Wu Q; Zhu X; Fang F; Zhang W; Xing W; Li Q; Song T; Lu W; Li H
Neoplasma; 2023 Dec; 70(6):811-818. PubMed ID: 38247334
[TBL] [Abstract] [Full Text] [Related]
18. [Efficacy analysis of hepatic arterial infusion chemotherapy combined with targeted and immune therapy followed by
Wang M; Zhou ZG; Lu TY; Du KP; Li S; Gao F; Li YD; Gao MY
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):290-296. PubMed ID: 38246774
[No Abstract] [Full Text] [Related]
19. Decoding the multifaceted interventions between human sirtuin 2 and dynamic hepatitis B viral proteins to confirm their roles in HBV replication.
Piracha ZZ; Saeed U; Piracha IE; Noor S; Noor E
Front Cell Infect Microbiol; 2023; 13():1234903. PubMed ID: 38239506
[TBL] [Abstract] [Full Text] [Related]
20. Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning.
Liu Y; Li H; Zeng T; Wang Y; Zhang H; Wan Y; Shi Z; Cao R; Tang H
Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38197309
[TBL] [Abstract] [Full Text] [Related]
[Next]
